Literature DB >> 3002612

Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung.

L Y Korman, D N Carney, M L Citron, T W Moody.   

Abstract

Bombesin/gastrin releasing peptide-like immunoreactivity (BLI) is found in the majority of small cell carcinoma of the lung (SCCL) cell lines examined. Because BLI is present in high concentration in SCCL we studied the mechanism of BLI secretion from several SCCL cell lines and in patients with SCCL. In cell line NCI-H345 the structurally related polypeptide hormones secretin, vasoactive intestinal peptide, and peptide histidine isoleucine as well as theophylline, a phosphodiesterase inhibitor, N6,O2'-dibutyryl cyclic adenosine 3':5'-monophosphate, a cyclic nucleotide analogue, increased BLI release by 16-120% and cyclic adenosine 3':5'-monophosphate by 36-350%. Similar results were obtained in SCCL cell line NCI-H209. i.v. injection of secretin (2 units/kg) significantly increased plasma BLI in 2 patients with extrapulmonary SCCL. These data suggest that SCCL cells possess receptors for secretin/vasoactive intestinal peptide and that receptor occupation stimulates in vitro and in vivo BLI secretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Authors:  Terry W Moody; Veronica Sancho; Alessia di Florio; Bernardo Nuche-Berenguer; Samuel Mantey; Robert T Jensen
Journal:  Peptides       Date:  2011-06-25       Impact factor: 3.750

Review 3.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

4.  Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.

Authors:  Terry W Moody; Tomoo Nakagawa; Yang Kang; Sonia Jakowlew; Daniel Chan; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

5.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors:  K Maruno; A Absood; S I Said
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

6.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 7.  Autocrine growth factors and solid tumor malignancy.

Authors:  J H Walsh; W E Karnes; F Cuttitta; A Walker
Journal:  West J Med       Date:  1991-08

8.  Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects.

Authors:  G Bepler; M Rotsch; G Jaques; M Haeder; J Heymanns; G Hartogh; P Kiefer; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 9.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

10.  Characterization of ligand binding and processing by gastrin-releasing peptide receptors in a small-cell lung cancer cell line.

Authors:  C Cardona; N M Bleehen; J G Reeve
Journal:  Biochem J       Date:  1992-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.